MassMutual Private Wealth & Trust FSB Makes New $209,000 Investment in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

MassMutual Private Wealth & Trust FSB purchased a new stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 28,100 shares of the company’s stock, valued at approximately $209,000.

A number of other institutional investors also recently modified their holdings of LFCR. Marshall Wace LLP boosted its stake in Lifecore Biomedical by 87.3% in the second quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock valued at $1,540,000 after buying an additional 139,887 shares in the last quarter. 272 Capital LP lifted its holdings in shares of Lifecore Biomedical by 511.1% in the third quarter. 272 Capital LP now owns 143,480 shares of the company’s stock worth $707,000 after acquiring an additional 120,002 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Lifecore Biomedical in the 2nd quarter valued at approximately $327,000. Geode Capital Management LLC boosted its stake in shares of Lifecore Biomedical by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock valued at $2,948,000 after purchasing an additional 55,703 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Lifecore Biomedical by 2,640.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock valued at $268,000 after purchasing an additional 52,414 shares during the last quarter. Institutional investors and hedge funds own 83.36% of the company’s stock.

Insider Activity

In other news, CEO Paul Josephs bought 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the chief executive officer now directly owns 559,717 shares in the company, valued at approximately $3,212,775.58. This represents a 3.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 28.21% of the company’s stock.

Wall Street Analysts Forecast Growth

LFCR has been the subject of several research reports. Stephens reissued an “equal weight” rating and issued a $6.00 price objective on shares of Lifecore Biomedical in a research note on Friday, January 3rd. Craig Hallum raised their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd.

Lifecore Biomedical Stock Performance

Shares of Lifecore Biomedical stock opened at $6.43 on Thursday. The stock has a market cap of $238.10 million, a price-to-earnings ratio of -11.48 and a beta of 0.98. Lifecore Biomedical, Inc. has a twelve month low of $3.68 and a twelve month high of $8.90. The company’s fifty day moving average is $7.05 and its 200 day moving average is $5.92. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Sell-side analysts forecast that Lifecore Biomedical, Inc. will post -1 EPS for the current year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.